Modella AI vs Paige (2026)
Both build pathology foundation models, but Paige also sells authorized clinical AI. Paige Prostate holds De Novo authorization (DEN200080) as an adjunct for prostate biopsies, and Paige sells suites across several cancers, the Alba copilot and the Virchow models; Tempus acquired it in August 2025. Modella's PathChat 2 is a copilot for research and education, its diagnostic version holds a Breakthrough Device Designation, and AstraZeneca has acquired Modella.
- You want a generative copilot for pathology research or teaching.
- You work with AstraZeneca's oncology research.
- You want to evaluate models built on the Mahmood Lab's research published in Nature.
- You want an authorization that covers the AI: Paige Prostate's De Novo.
- You want clinical suites across prostate, breast, gastrointestinal and pan cancer work, with the Alba copilot.
- You want foundation models you can use, some of them open sourced in 2024.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Modella AI and Paige are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Modella AI | Paige |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2023 | 2018 |
| Headquarters | Boston, Massachusetts, United States | New York, New York, United States |
| Website | modella.ai | paige.ai |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Paige
-
Product / capability
Paige launched an AI tool that screens 505 genes directly from H and E stained pathology slides, without requiring next generation sequencing as a first step.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Boston biomedical AI company, acquired by AstraZeneca, building generative and agentic tools for pathology. PathChat combines pathology foundation models pretrained on histology image and image text data with a custom trained multimodal large language model, and PathChat 2 is offered as a copilot for research and education that can be used from a microscope, a slide viewer or a smartphone; Judith is an agent for automating AI model development on biomedical images.
Source: AI Health Index, September 2026
Computational pathology company that produced the first FDA authorized AI based digital pathology product: Paige Prostate received De Novo authorization (DEN200080) in September 2021 as an adjunct that flags the area of a digitized prostate biopsy most likely to contain cancer, used with a specified scanner and the company's FullFocus viewer.
Source: AI Health Index, September 2026
Questions buyers ask
How are Modella AI and Paige priced and sold?
For Modella AI, the company is venture backed and private, so there is no listing driven financial disclosure either.
With Paige, the suites and the platform carry no list price, tier structure, per slide or per case rate, or subscription level. Evaluation runs through a trial request and commercial terms through contact with the company, and the platform has been distributed through a cloud marketplace, which can carry standard terms. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Modella AI and Paige handle patient data?
In Modella AI's case, the site states no retention period, deidentification practice or training use for images submitted to PathChat, though the privacy policy may address them.
Paige's privacy policy is scoped to the company's websites and online services, and the personal information it lists is business and website contact data collected through analytics and marketing tools; it does not describe what happens to the whole slide images a laboratory processes through the Paige Platform or Alba. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Modella AI and Paige?
With Modella AI, the company links the Nature (2024) paper describing PathChat and its evaluation on pathology diagnostic questions against other multimodal models, and Nature Biotechnology work on the underlying foundation models, from the Mahmood Lab at Mass General Brigham.
In Paige's case, the current home page cites no study, customer outcome or deployment figure for any suite. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Paige's current site does not state the regulatory status of each suite, and a Breakthrough Device Designation on either company's tool is not an authorization. Both have been acquired, by Tempus and AstraZeneca. Rewritten 28 Sep 2026 after both records were reviewed.